ADA
Diabetes & Cardiovascular Disease
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among patients with diabetes. Therefore, managing ASCVD risk is crucial in preventing the progression of atherosclerosis and reducing serious events like heart attacks and strokes in individuals with diabetes.
Published
Categorized as ADA, Clinical Guidelines, Diabetes Care, Heart Health, Insights from Dr. Tashko, Lipid Health
Hypertension and Diabetes
Diabetes specialists and hypertension specialists should integrate the 2020 American Diabetes Association guidelines into their clinical practice. These guidelines emphasize achieving specific blood pressure targets for different patient groups. For instance, adults at high risk of ASCVD should aim for BP levels below 130/80 mmHg, while those with gestational diabetes should target below 135/85 mmHg. Individuals with low ASCVD risk should aim for BP levels below 140/90 mmHg. Lifestyle modifications and appropriate medications are key…
Published
Categorized as ADA, Blog, Clinical Guidelines, Diabetes Care, Hypertension, Insights from Dr. Tashko
Medications for Type 2 Diabetes
It is important to note that the drug recommendations provided here are general and serve only as a guideline. The ultimate clinical decision should consider factors such as medication tolerability, cost, clinical context, glucose control, the patient’s weight loss goals, comorbidities, and patient preferences.
Published
Categorized as ADA, Blog, Clinical Guidelines, Diabetes Care, Drug Information, Insights from Dr. Tashko
Key Revisions of 2020 ADA Guidelines
Here you can find the critical modifications in the 2020 ADA guidelines. Particular emphasis is placed on pharmacological therapy with GLP-1 agonists or SGLT-2 inhibitors for patients with established cardiovascular disease, heart failure, or chronic kidney disease. Guidelines are published yearly in January.
Published
2019 ADA guidelines: Key Revisions
You can find here key changes in ADA guidelines. They are published in Diabetes Care once yearly in the month of January. Specific topics will be further discussed and posted here. Stay tuned! GT
Published
Review of 2018 ADA guidelines: dyslipidemia in the context of diabetes
ADA recommendations are released each January. Below is a succinct ACP review of guidelines in screening, treatment goals, lifestyle intervention, and drug approach to dyslipidemia in the setting of diabetes mellitus. LDL-cholesterol is still a main target. Charts depict indications and doses of statins, the mainstay therapy to diabetic lipid disorders. GT
Published
Categorized as ADA, Blog, Clinical Guidelines, Diabetes Care, Insights from Dr. Tashko, Lipid Health
Review of 2018 ADA Guidelines: hypertension in the context of diabetes
ADA standards are released each January. Here is a succinct ACP review of guidelines in screening, diagnosis, treatment goals, lifestyle intervention, and drug approach to hypertension in the setting of diabetes mellitus. The chart depicts nicely the flow process of how to initiate and intensify the pharmacological therapy. GT
Published
Categorized as ADA, Blog, Clinical Guidelines, Diabetes Care, Hypertension, Insights from Dr. Tashko
2017 ADA guidelines: dyslipidemia and diabetes
Below you can find ADA recommendations on screening, cardiovascular risks, and treatment of dyslipidemia in the context of diabetes. As always improve lifestyle choices first. If ASCVD likelihood is still high then add medications. Statins are first-line, either of moderate or high intensity. Statin selection would depend on age, CVD status, and contributing factors. Statin plus PCSK9 inhibitor or statin plus zetia could be used in adults with residual ASCVD risk. Statin plus fenofibrate is…
Published
Categorized as ADA, Blog, Clinical Guidelines, Diabetes Care, Insights from Dr. Tashko, Lipid Health
2017 ADA guidelines: diabetes during pregnancy
Below you can find ADA standards on proper A1c targets, blood pressure range, retinopathy monitoring and medications used in preexisting and gestational diabetes. The preferred medications during pregnancy are insulin, metformin and glyburide. Recommendations are listed below with slightly modified wording for easier and succinct reading: GT
Published
2017 ADA guidelines: metabolic surgery for type 2 diabetes
Obesity is a pro-inflammatory state contributing to insulin resistance and type 2 diabetes. Starting with jejuno-ileal bypass in 1954 by Kremer and intestinal bypass in 1967 by Mason, various techniques of the malabsorption surgery have been developed, researched and applied over the decades. They have shown good results in reducing hyperglycemia, the number of diabetic medications and excessive body weight. Guidance on the importance and indications of metabolic surgery for type 2 diabetes were published…
Published
Categorized as ADA, Blog, Clinical Guidelines, Diabetes Care, Insights from Dr. Tashko, Obesity Care
2017 ADA position statement: hypertension in diabetes
High blood pressure is common in patients with diabetes. Both hypertension and diabetes are independent risk factors for poor cardiovascular outcomes. Obviously the concomitant presence of both HTN and DM in an individual magnifies the chance for CVD events. It is important to screen, diagnose and treat high blood pressure appropriately in someone with diabetes, particularly type 2. ADA published a position statement on the subject in Diabetes Care, September 2017. The article is comprehensive…
Published
Categorized as ADA, Blog, Clinical Guidelines, Diabetes Care, Hypertension, Insights from Dr. Tashko
2017 ADA Guidelines: Glucose Targets
Last ADA standards were published in January 2017. You could find below the recommended glucose aims for patients with type 1 and type 2 diabetes. Guidelines offer flexibility on A1c targets from <6.5-8.0% depending on person’s age, life expectancy, polypharmacy, disease duration, hypoglycemia frequency and comorbidities. GT
Published